NFE2L3抗体;NFE2L3 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: MCF7 and LO2 cell lysates, Primary antibody: P13751(NFE2L3 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

The NFE2L3 antibody targets the nuclear factor erythroid 2-related factor 3 (NFE2L3), also known as NRF3. a transcription factor encoded by the *NFE2L3* gene. NFE2L3 belongs to the Cap‘n’Collar (CNC) family of proteins and plays a role in regulating cellular responses to oxidative stress, metabolism, and proliferation. Unlike its well-studied homolog NRF2 (NFE2L2), which is a master regulator of antioxidant response elements (AREs), NFE2L3 exhibits distinct regulatory mechanisms and tissue-specific expression, with higher levels in the liver, placenta, and certain cancer cells. It is anchored to the endoplasmic reticulum membrane under basal conditions and translocates to the nucleus upon proteolytic activation, where it modulates genes involved in proteasome function, lipid metabolism, and cell cycle progression.

Antibodies against NFE2L3 are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate NFE2L3's role in diseases like cancer, where it may promote tumorigenesis by enhancing proteasome activity or metabolic reprogramming. Commercial NFE2L3 antibodies are typically validated for specificity using knockout cell lines or tissues. Researchers also employ these antibodies to explore interactions with binding partners, post-translational modifications, and its crosstalk with other signaling pathways, such as the Keap1-NRF2 axis. Understanding NFE2L3's complex biology through antibody-based assays contributes to insights into therapeutic targeting of oxidative stress-related disorders and cancer.